Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Higher dosage of cocaine vaccine is being tested by researchers at Yale

Yale University : 12 April, 2006  (New Product)
Yale researchers are enrolling five cocaine addicts in a clinical trial in New Haven as part of an ongoing investigative effort to determine the safety and efficacy of the cocaine vaccine, TA-CD.
Yale researchers are enrolling five cocaine addicts in a clinical trial in New Haven as part of an ongoing investigative effort to determine the safety and efficacy of the cocaine vaccine, TA-CD.

If all goes well, a second group of five to six cocaine addicts will be enrolled in the Phase Two trial in three months and will be administered a higher dose of the vaccine, again to test its safety and efficacy.

'The patients have to be followed carefully for any medical abnormalities,' said Thomas Kosten, M.D., professor of psychiatry at Yale School of Medicine and principal investigator of the study funded by the National Institute on Drug Abuse. 'We are now still working with the old dose, but, assuming this turns out well with the five subjects, we will escalate to a higher dose of the vaccine and potentially look at a booster dose.'

Kosten said he hoped that within six months the research team could begin a large scale, randomized clinical trial of the vaccine. The 120 cocaine and opiate addicts in that larger study will be maintained on methadone to help insure they remain in the trial.

The vaccine alerts the immune system to the presence of cocaine in the blood, thereby stimulating antibodies that prevent the cocaine molecule from penetrating the blood brain barrier and preventing the addict from experiencing the sought after euphoric effect. The 'high' that addicts experience when they relapse reinforces their addiction.

The vaccine is being developed by Xenova, a biotechnology firm in Great Britain. The company estimates that each year more than a million Americans seek treatment for cocaine addiction.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo